Accessibility Menu
Neurocrine Biosciences logo

Neurocrine Biosciences(NASDAQ) NBIX

Current Price$174.63
Market Cap$18.00BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1996)+1,332%
5 Year+82%
1 Year+36%
1 Month+13%
Neurocrine Biosciences last closing stock price
MetricPriceDate
Last closeUSD 179.052026-07-21
Neurocrine Biosciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+4.07%USD 172.042026-07-14
1 month+13.12%USD 158.292026-06-18
3 month+36.49%USD 131.182026-04-22
Year to date+26.24%USD 141.832025-12-31
1 year+35.82%USD 131.832025-07-21
3 year+81.24%USD 98.792023-07-21
5 year+82.46%USD 98.132021-07-22
Since inception+1,332.4%USD 12.501996-05-23

Neurocrine Biosciences Financials at a Glance

Market Cap

$18.00BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$3.10B

Net Income (TTM)

$668.60M

EPS (TTM)

$6.50

P/E Ratio

27.53

Dividend

$0.00

Beta (Volatility)

0.62 (Low)

Price

$174.63

Volume

12,983

Open

$179.19

Previous Close

$179.05

Daily Range

$174.23 - $179.56

52-Week Range

$122.14 - $181.18

Estimated Earnings Date

Jul 30, 2026

NBIX News

Foolcom-Featured.png

Neurocrine (NBIX) Q2 Revenue Jumps 17%

Motley Fool Markets TeamAug 1, 2025
Copy of TMF YT Thumbnails (10)

Neurocrine Biosciences: A Smart Biotech Bet With Blockbuster Potential

Motley Fool YouTubeMar 26, 2025
GettyImages-1058581360

Why Neurocrine Biosciences Stock Sank Today

Eric VolkmanFeb 10, 2025
GettyImages-1346675569.jpg

Neurocrine Biosciences Reports Mixed Q4

Motley Fool Markets TeamFeb 7, 2025
Neurology 2.jpg

Neurocrine Tops Expectations in Q3

Motley Fool Markets TeamOct 30, 2024
Two people seated at a lab desk featuring a PC screen and microscope

Why Neurocrine Biosciences Stock Was Tumbling This Week

Eric VolkmanAug 30, 2024
Neurology.jpg

Neurocrine Biosciences' Revenue and Adjusted Income Surge

Motley Fool Markets TeamAug 1, 2024
falling chart man watching computer screen

Why Neurocrine Biosciences Shares Fell Nearly 10% Today

James BrumleyNov 2, 2021
Page 1

NBIX: Motley Fool Moneyball Superscore

73

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Neurocrine Biosciences

Neurocrine develops medicines for people with neurological and hormonal disorders. Its main drugs help those with involuntary movements or hormone imbalances. These treatments improve daily life for patients with conditions like tardive dyskinesia or congenital adrenal hyperplasia.

Pill Bottles and Brainwaves: What Neurocrine Sells

  • INGREZZA (valbenazine): Treats involuntary movements in adults, mainly tardive dyskinesia; over 99% of 2024 product sales.
  • CRENESSITY (crinecerfont): Addresses hormone disorder CAH in adults and children; launched December 2024, no material sales yet.
  • Royalties from AbbVie: Earns a share from sales of endometriosis and uterine fibroid drugs; less than 1% of 2024 revenue.
  • Pipeline Products: Developing drugs for epilepsy, depression, and schizophrenia; no current revenue contribution.

Growth Spurts and Strategic Moves

  • Launched CRENESSITY in the U.S. in December 2024 for CAH treatment.
  • Expanded sales force and opened new San Diego campus in 2024.
  • Formed partnerships with AbbVie, Mitsubishi Tanabe Pharma, Takeda, and others for research and global reach.
  • Terminated ONGENTYS license with BIAL Portela in December 2023.
  • Completed $300 million share repurchase in February 2025.

Why Neurocrine Stands Out (Without the Hype)

Neurocrine focuses on under-treated brain and hormone disorders, using a specialty pharmacy model for distribution. Its patent protections extend exclusivity for key drugs into the late 2030s. The company relies on partnerships for global access and pipeline development.

Five Things You Need to Know

  • Revenue was $2.36 billion in 2024, up 24.8% from 2023.
  • INGREZZA made up over 99% of 2024 product sales.
  • Operating income was $570.5 million in 2024, up 127% from 2023.
  • Cash, equivalents, and securities totaled $1.82 billion at year-end 2024.

Bottom Line

Neurocrine has grown by focusing on niche neurological and hormonal conditions. Its business relies on a single flagship drug, but it is expanding its pipeline and partnerships.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

2,000

CEO

Kyle W. Gano, PhD, MBA

Website

www.neurocrine.com

Headquarters

San Diego, CA 92130, US

NBIX Financials

Key Financial Metrics (TTM)

Gross Margin

98.17%

Operating Margin

25.19%

Net Income Margin

21.55%

Return on Equity

21.64%

Return on Capital

16.88%

Return on Assets

13.63%

Earnings Yield

3.63%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$18.00BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

100.55M

Volume

12.98K

Avg. Volume

1.20M

Financials (TTM)

Gross Profit

$3.05B

Operating Income

$781.50M

EBITDA

$955.80M

Operating Cash Flow

$863.70M

Capital Expenditure

-$32.40M

Free Cash Flow

$831.30M

Cash & ST Invst.

$1.32B

Total Debt

$406.20M

Neurocrine Biosciences Performance Analysis

Neurocrine Biosciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 1,488,700,00031.3%
20232023-12-31USD 1,887,100,00026.8%
20242024-12-31USD 2,355,300,00024.8%
20252025-12-31USD 2,860,500,00021.4%
Neurocrine Biosciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3020.1%
Q32025-09-3015.6%
Q42025-12-311.3%
Q12026-03-311.1%
Neurocrine Biosciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 1.5670.7%
20232023-12-31USD 2.4758.3%
20242024-12-31USD 3.2933.1%
20252025-12-31USD 4.6741.9%
Neurocrine Biosciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-301225.0%
Q32025-09-3092.5%
Q42025-12-31-27.5%
Q12026-03-3129.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$814.50M

+42.2%

Gross Profit

$800.70M

+42.1%

Gross Margin

98.31%

N/A

Market Cap

$18.00BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$9.00M

N/A

Employees

2,000

N/A

Net Income

$197.90M

+2405.1%

EBITDA

$254.10M

+711.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$1.32B

+39.5%

Total Debt

$406.20M

-9.2%

Accounts Receivable

$768.10M

+48.9%

Inventory

$64.50M

+9.1%

Long Term Debt

$406.20M

-9.2%

Short Term Debt

$0.00

N/A

Return on Assets

13.63%

N/A

Return on Invested Capital

19.18%

N/A

Free Cash Flow

$136.70M

+152.7%

Operating Cash Flow

$145.80M

+125.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
HOLXHologic, Inc.
$76.01+0.00%
VTRSViatris Inc.
$17.21-2.18%
COOThe Cooper Companies, Inc.
$70.64-0.52%
ELANElanco Animal Health Incorporated
$25.83+1.35%

Trending Stocks

Symbol / CompanyPricePrice Chg
ZCMDZhongchao
$5.54+2.77%
SOFISoFi Technologies
$17.16-0.03%
TET1 Energy Inc.
$6.12+0.00%
MARAMara Holdings
$12.50+0.02%

Questions About NBIX

What is the current price of Neurocrine Biosciences?

Neurocrine Biosciences is trading at $174.63 per share.

What is the 52-week range for Neurocrine Biosciences?

Over the past 52 weeks, Neurocrine Biosciences has traded between $122.14 and $181.18.

How much debt does Neurocrine Biosciences have?

As of the most recent reporting period, Neurocrine Biosciences reported total debt of $406.20M.

How much cash does Neurocrine Biosciences have on hand?

Neurocrine Biosciences reported $266.50M in cash and cash equivalents in its most recent financial results.

What is Neurocrine Biosciences’s dividend yield?

Neurocrine Biosciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services